Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 4/20 | 0.46 |
| ▸ | BCL2 | P10415 | 7/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488074 | 0.93 | AGTR1 (0.43) | AGTR1BCL2MCL1ALOX5APPTGER1 | |
| SCHEMBL6501134 | 0.89 | BCL2 (0.47) | BCL2MCL1MRGPRX4 | |
| SCHEMBL6500043 | 0.88 | BCL2 (0.45) | AGTR1BCL2MCL1 | |
| SCHEMBL6500822 | 0.87 | AGTR1 (0.47) | AGTR1BCL2MCL1 | |
| SCHEMBL6492366 | 0.85 | PIK3C2B (0.45) | BCL2MCL1ALOX5APMRGPRX4 | |
| SCHEMBL6501228 | 0.84 | BCL2 (0.40) | AGTR1BCL2MCL1ALOX5APMRGPRX4 | |
| SCHEMBL6500552 | 0.83 | MRGPRX4 (0.49) | BCL2MCL1ALOX5APMRGPRX4PTGER1 | |
| SCHEMBL6502827 | 0.83 | ALOX5AP (0.41) | AGTR1BCL2MCL1ALOX5APMRGPRX4 | |
| SCHEMBL6498787 | 0.82 | BCL2 (0.40) | AGTR1BCL2MCL1ALOX5AP | |
| SCHEMBL6488562 | 0.81 | AGTR1 (0.41) | AGTR1BCL2MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | AGTR1 2045/4885BCL2 774/4885MCL1 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.